Showing 2911-2920 of 4063 results for "".
- SightGlass Vision to Present New Myopia Control Research at 2026 Netherlands Contact Lens Congresshttps://modernod.com/news/sightglass-vision-to-present-new-myopia-control-research-at-2026-netherlands-contact-lens-congress/2485953/Key Takeaways Two new studies show that Sigh
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S
- Sight Sciences Announces Fee Schedule Establishment for TearCare Dry Eye Procedurehttps://modernod.com/news/sight-sciences-announces-fee-schedule-establishment-for-tearcare-dry-eye-procedure/2484193/Sight Sciences announced that two Medicare Administrative Contractors (MACs), Novitas Solutions and First Coast Service Options (FCSO), each established jurisdiction-wide pricing for CPT code 0563T (evacuation of meibomian glands, using heat delivered through wearable, open-eye eye
- American Academy of Optometry Announces 2025 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2025-award-recipients/2484131/Each year, the American Academy of Optometry (AAOpt) recognizes distinguished individuals whose contributions advance the profession of optometry and vision science. The Academy’s awardees are nominated by fellows and are based on contributions made in t
- NASA Astronauts to Headline Heidelberg Engineering’s 2025 International Spectralis Symposiumhttps://modernod.com/news/nasa-astronauts-to-headline-heidelberg-engineerings-2025-international-spectralis-symposium/2482818/Heidelberg Engineering announced that NASA astronauts Warren Hoburg and Tyson Brunstetter, OD, PhD, will lead the keynote presentation at the company’s
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- BVI Introduces Serenity and Serenity Toric IOLshttps://modernod.com/news/bvi-to-unveil-serenity-and-serenity-toric-premium-monofocal-iols-at-escrs/2482420/BVI has introduced the Serenity and Serenity Toric premium monofocal IOLs, which it plans to launch in Europe at the upcoming ESCRS congress in Barcelona. These non-diffractive, aspheric IOLs represent the second generation of BVI’s Isopure family, launched in 2019
- Zeiss to Unveil Several New Innovations at ESCRS 2024https://modernod.com/news/zeiss-to-unveil-several-new-innovations-at-escrs-2024/2482415/Zeiss will showcase its latest advancements in cataract and corneal refractive surgery at the upcoming European Society of Cataract and Refractive Surgeons (ESCRS) conference, taking place from September 6-10 in Bar
- Bausch + Lomb Publishes Teneo Excimer Laser Clinical Trial Resultshttps://modernod.com/news/bausch-lomb-publishes-teneo-excimer-laser-clinical-trial-results/2482393/Bausch + Lomb announced the publication of clinical trial results for its Teneo Excimer Laser in the August issue of the Journal of Refractive Surgery. These findings supported the FDA approval of the Teneo platform for LASIK in January 2024, specifically for myopia and myopic astig